๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bhubaneswar
Clinical trial register · India

Clinical Trials in Bhubaneswar

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company14 All India Institute of Medical Sciences, Bhubaneswar9 AstraZeneca7 Boehringer Ingelheim6 Janssen Research & Development, LLC6
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
77 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Ahmedabad, Bhubaneswar, Chandigarh, Ernฤkulam, Hyderabad, Jaipur, Kochi, Kolkata
2025-10-15
Recruiting
Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus
NCT07131813Oral Lichen Planus
All India Institute of Medical Sciences, Bhubaneswar
Phase 4
60
Bhubaneswar
2025-10-10
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Bangalore, Bengaluru, Bhubaneswar, Ernฤkulam, Gurugram, Hyderabad, Jaipur, Ludhiana
2025-10-01
Not yet open
Effect of RhizomK on Testosterone Levels, the Anabolic Response to Exercise and Overall Quality of Life in Physically Active Healthy Males
NCT07143474Adult Healthy Volunteers
All India Institute of Medical Sciences, Bhubaneswar
Not applicable
60
Bhubaneswar
2025-10
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer
NCT07478900Breast Cancer (Locally Advanced or Metastatic), Tattoo Skin Markers, Neoadjuvant Chemoimmunotherapy
All India Institute of Medical Sciences, Bhubaneswar
Not applicable
30
Bhubaneswar
2025-09-10
Recruiting
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07044687Acute Myeloid Leukemia
AbbVie
Phase 4
100
Gurgaon, Bengaluru, Thiruvananthapuram, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai
2025-07-24
Recruiting
Community-Based Cohort Study of Hidden Malaria Infections, Diagnostic Gaps, & Mosquito Vector Dynamics in Odisha, India
NCT07770048Malaria, Asymptomatic Parasitaemia
London School of Hygiene and Tropical Medicine
Observational
3,000
Bhubaneswar, Raurkela
2025-05-02
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Bangalore, Bhubaneswar, New Delhi, Ulhasnagar
2025-04-30
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Visakhapatnam, Ahmedabad, Thiruvananthapuram, Mumbai, New Delhi, Bhubaneswar, Madurai, Hyderabad
2025-04-24
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Immutep S.A.S.
Phase 3
756
Bangalore, Bhubaneswar, Chennai, Kolkata, New Delhi, Thane, Thiruvananthapuram, Varanasi
2025-03-21
Recruiting
Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder
NCT06803485Somatic Symptom Disorder (DSM-V)
All India Institute of Medical Sciences, Bhubaneswar
Phase 4
84
Bhubaneswar
2025-03-11
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
552
Ahmedabad, Bhubaneswar, Hyderabad, Kolkata, Mumbai, Mysuru, New Delhi, Noida
2025-02-21
Recruiting
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (โ‰ฅ18 Years) Primary IgA Nephropathy?
NCT06676384IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
Christian Medical College, Vellore, India
Phase 4
585
Nadiฤd, Mysuru, Udupi, Mumbai, Delhi, Bhubaneswar, Puducherry, Chennai
2025-02-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
750
Ahmedabad, Bhubaneswar, Hubballi, Kolkata, Mysuru, New Delhi, Noida, Surat
2025-01-09
Recruiting
Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:
NCT06737822Oral Cancer, Head and Neck Neoplasms
All India Institute of Medical Sciences, Jodhpur
Phase 3
346
Bhubaneswar, Jodhpur, Bathinda, Dehradun, Lucknow, Rishikesh, Udaipur
2024-12-20
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Amravati, Bhubaneswar, Hyderabad, Kolhฤpur, Mumbai, Mysuru, Namakkal, Pune
2024-10-04
Recruiting
Efficacy of EBPSI on Future Suicide Risk Among Adolescent Suicide Attempters
NCT06474221Suicide, Attempted
University of Pittsburgh
Not applicable
168
Bengaluru, Bhubaneswar
2024-08-31
Recruiting
EASi-KIDNEYโ„ข (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Bangalore, Bathinda, Bhubaneswar, Bilฤspur, Chandigarh, Chennai, Dwฤrka, Faridabad
2024-08-30
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Ahmedabad, Bhubaneswar, Chennai, Coimbatore, Jaipur, Kochi, Ludhiana, New Delhi
2024-07-18
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
GlaxoSmithKline
Phase 3
88
Gokul Shirgoan, Apex Wellness Hospital, Bangalore, Belagavi, Bhubaneswar, Gurgaon, New Delhi
2024-06-10
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Eli Lilly and Company
Phase 3
10,000
Allahฤbฤd, Bangalore, Bhubaneswar, Bikaner, Chennai, Dehradun, Guntur, Kanpur
2024-04-30
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Mumbai, Pune, Bengaluru, Bhubaneswar, Gurgaon, Hyderabad, Nashik, Nehru Nagar Belagavi Karnataka 590010
2024-03-21
Rows per page Showing 26–50 of 77
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/bhubaneswar

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.